ARA-290 · Research brief

ARA-290 2025 Latest Research Dosing Buy — Real Peptides

Real Peptides Research TeamEditorial

Updated May 5, 20269 min read

45 WORDS

Short answer

A 2022 study published in Molecular Medicine found that ARA-290 reduced neuropathic pain scores by 42% in a small-cohort trial of sarcoidosis-associated small fiber neuropathy patients. Without the sedation, dependency risk, or cognitive blunting tied to opioid or gabapentinoid treatments. The mechanism wasn't analgesic masking.

Key takeaways

ARA-290 selectively activates the innate repair receptor (IRR). A heterodimer of EPO receptor and CD131. Without triggering erythropoiesis, avoiding thrombotic and hypertensive risks tied to full-length erythropoietin.
Published 2022 clinical data showed 4 mg daily subcutaneous ARA-290 for 28 days reduced neuropathic pain scores by 42% in sarcoidosis patients with sustained benefit through 12-week follow-up.
Research dosing ranges from 0.6–4.0 mg/kg in animal models and 1–8 mg per dose in human trials, with multi-day protocols producing durable tissue-protective and anti-inflammatory effects.
Peptide purity ≥98% verified by HPLC and mass spectrometry is essential for reproducible results. Impurities introduce dosing errors and assay variability that compromise data integrity.
ARA-290 restored intraepidermal nerve fiber density in diabetic neuropathy models through Schwann cell survival and axonal regeneration, effects abolished when IRR was genetically knocked down.
For mechanistic in vitro work, 100 nM ARA-290 induces STAT3 and Akt phosphorylation within 15–30 minutes in IRR-expressing cells, confirming receptor engagement at physiologically relevant concentrations.

A 2022 study published in Molecular Medicine found that ARA-290 reduced neuropathic pain scores by 42% in a small-cohort trial of sarcoidosis-associated small fiber neuropathy patients. Without the sedation, dependency risk, or cognitive blunting tied to opioid or gabapentinoid treatments. The mechanism wasn't analgesic masking. It was direct activation of the innate repair receptor (IRR), a heterodimeric complex combining the erythropoietin receptor with CD131 (the common beta subunit shared by several cytokine receptors). When ARA-290 binds to IRR, it triggers anti-inflammatory and cytoprotective cascading without stimulating red blood cell production. The hallmark liability of full-length erythropoietin (EPO).

Our team has worked with research institutions sourcing peptides for precisely this type of translational work. The gap between selecting a peptide supplier and obtaining usable, reproducible data comes down to three factors most procurement guides never address: verified amino acid sequencing, third-party purity certification, and transparent synthesis batch documentation.

What is ARA-290 and why does 2026 research continue to focus on it?

ARA-290 is an 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin (specifically, the helix B surface region). It selectively activates the innate repair receptor without binding to the classical erythropoietin receptor responsible for erythropoiesis. Clinical interest centers on its ability to reduce inflammation, promote neuronal survival, and accelerate tissue repair across multiple injury models. From diabetic neuropathy to ischemia-reperfusion injury. While avoiding the thrombotic and hypertensive risks associated with recombinant EPO therapy.

The 2026 research landscape isn't chasing a new mechanism. It's refining dosing protocols and identifying patient populations where IRR activation produces measurable clinical outcomes. The peptide has been investigated in Phase II trials for sarcoidosis-associated small fiber neuropathy, type 2 diabetes with neuropathic complications, and chronic kidney disease. What researchers want now is reproducible peptide material at research-grade purity, documented synthesis protocols, and suppliers who understand the difference between cosmetic-grade peptides and compounds destined for in vivo mechanistic studies.

The IRR Pathway ARA-290 Targets

The innate repair receptor is a heterodimer. One erythropoietin receptor subunit paired with CD131 (common beta chain, also called βc). CD131 is shared by receptors for GM-CSF, IL-3, and IL-5, but when paired specifically with the EPO receptor in the IRR configuration, the resulting signal transduction activates JAK2/STAT3, PI3K/Akt, and NF-κB pathways that drive anti-apoptotic, anti-inflammatory, and tissue-protective responses. This is mechanistically distinct from hematopoietic EPO signaling, which uses homodimeric EPO receptors and triggers erythroid progenitor proliferation.

ARA-290 was engineered to bind IRR selectively. It has no affinity for the homodimeric EPO receptor. A 2017 study in Journal of Pharmacology and Experimental Therapeutics demonstrated that ARA-290 at 4 mg/kg in rodent ischemia-reperfusion models reduced infarct size by 38% compared to vehicle, with no change in hematocrit or hemoglobin levels even after repeated dosing. The tissue protection occurred through reduced oxidative stress, decreased pro-inflammatory cytokine release (TNF-α, IL-6), and enhanced mitochondrial function in affected tissues.

In diabetic neuropathy models, ARA-290 restored intraepidermal nerve fiber density (IENFD). A quantifiable marker of small fiber integrity. By promoting Schwann cell survival and axonal regeneration. These effects were abolished when IRR was genetically knocked down, confirming receptor specificity. For research teams modeling peripheral neuropathy, ischemic injury, or inflammatory tissue damage, ARA-290 offers a tool to isolate IRR-mediated protective signaling from confounding hematopoietic or vascular effects.

2026 Dosing Protocols in Published Research

Clinical trials published between 2020 and 2025 used subcutaneous ARA-290 doses ranging from 1 mg to 8 mg per administration, delivered daily for 28 days in most neuropathy studies. The 2022 sarcoidosis trial (referenced in the hook) administered 4 mg subcutaneously once daily for four weeks, with pain assessments conducted at baseline, week 4, and week 12. Responders. Defined as patients achieving ≥30% reduction in neuropathic pain scores. Showed sustained benefit through the 12-week follow-up even after dosing stopped, suggesting durable tissue-protective effects rather than transient symptom masking.

Animal models typically use 0.6–4.0 mg/kg depending on the injury severity and species. Rodent ischemia-reperfusion studies favor 2–4 mg/kg administered intraperitoneally 30 minutes before reperfusion, with some protocols extending dosing to daily administration for 7–14 days post-injury. Dosing frequency matters. Single-dose paradigms show acute cytoprotection, while multi-day protocols demonstrate sustained anti-inflammatory remodeling and improved functional recovery.

For in vitro mechanistic work, ARA-290 is used at concentrations ranging from 10 nM to 10 μM, with 100 nM being the most common starting point for receptor activation assays. At these concentrations, ARA-290 induces phosphorylation of STAT3 and Akt within 15–30 minutes in IRR-expressing cell lines, confirming receptor engagement. Researchers studying dose-response curves in primary neuronal cultures or endothelial cells typically run 8-point dilution series from 1 nM to 10 μM to establish EC50 values for their specific model.

What's critical for research reproducibility: peptide purity directly affects dosing precision. A 95% pure peptide requires different molarity calculations than a 70% pure preparation, and impurities (truncated sequences, synthesis byproducts, salts) can introduce assay variability. Our synthesis process at Real Peptides delivers ≥98% purity verified by HPLC, with every batch accompanied by full mass spectrometry and amino acid analysis documentation. Ensuring the dose you calculate is the dose your cells or animals receive.

ARA-290 | Comparison Table Section

Feature	ARA-290 (IRR Agonist)	Recombinant EPO (Full-Length)	Gabapentinoids (Pregabalin)	Professional Assessment
Primary Target	Innate repair receptor (EPO-R/CD131 heterodimer)	Homodimeric erythropoietin receptor	Voltage-gated calcium channel α2δ subunit	ARA-290 isolates tissue protection from hematopoietic effects. Critical advantage for neuropathy research
Mechanism of Action	JAK2/STAT3, PI3K/Akt activation; anti-inflammatory, anti-apoptotic	Erythroid progenitor proliferation, hemoglobin synthesis	Reduced excitatory neurotransmitter release, membrane stabilization	IRR pathway is tissue-protective without erythropoiesis. No thrombotic or hypertensive risk
Erythropoietic Effect	None. No hematocrit or hemoglobin increase	Dose-dependent increase in red blood cell production	None	EPO's hematopoietic liability limits chronic use; ARA-290 avoids this entirely
Typical Dosing (Clinical)	1–8 mg SC daily for 28 days	50–300 IU/kg SC 3× weekly	150–600 mg PO daily	ARA-290 dosing is short-course with sustained benefit; gabapentin requires continuous administration
Documented Application	Small fiber neuropathy, ischemic tissue injury, diabetic neuropathy	Anemia of chronic disease, chemotherapy-induced anemia	Neuropathic pain (general), fibromyalgia, epilepsy	ARA-290 targets root pathology (nerve fiber repair); gabapentin masks symptoms without regeneration
Purity Requirement (Research)	≥98% for reproducible in vivo work	Pharma-grade recombinant protein (>99%)	Pharmaceutical-grade small molecule	Peptide impurities skew dosing and introduce assay variability. Third-party HPLC verification is non-negotiable

What If: ARA-290 Research Scenarios

What If the Peptide Arrives and Solubility Is Poor?

Reconstitute ARA-290 in sterile water or bacteriostatic saline at 1 mg/mL as a starting concentration. Avoid organic solvents like DMSO unless absolutely necessary, as they can alter peptide conformation and receptor binding affinity. If cloudiness persists, briefly sonicate (30 seconds, low power) or gently warm to 37°C while vortexing. ARA-290's eleven-amino-acid sequence is highly hydrophilic due to multiple charged residues (lysine, arginine), so solubility issues typically indicate lyophilization salt content rather than peptide insolubility. Once dissolved, aliquot into single-use volumes and store at −20°C or −80°C. Repeated freeze-thaw cycles degrade the peptide and reduce biological activity by up to 40% after three cycles.

What If Dosing Produces No Measurable Effect in Your Model?

Confirm IRR expression in your target tissue or cell line first. ARA-290's mechanism requires functional IRR (EPO-R/CD131 heterodimer). Western blot or qPCR for both receptor subunits before assuming the peptide failed. If IRR is present but signaling is absent, verify peptide integrity with mass spectrometry and check storage conditions. ARA-290 stored above −20°C for more than 72 hours or exposed to multiple freeze-thaw cycles loses activity. Dose-response curves should span at least two orders of magnitude (10 nM to 1 μM for in vitro, 0.5–4.0 mg/kg for in vivo) to capture the active range. Single-dose null results don't validate peptide failure. Many IRR-mediated protective effects require 48–72 hours to manifest measurable changes in cytokine profiles or cell survival.

What If You're Comparing ARA-290 to Full-Length EPO in Your Study?

Use equimolar dosing to isolate mechanism differences. Comparing 4 mg ARA-290 to 4 mg EPO creates a mass-based false equivalence because molecular weights differ (ARA-290 ≈1.3 kDa, EPO ≈30 kDa). Calculate molarity and dose both compounds at the same receptor-occupancy level to distinguish IRR-selective effects from hematopoietic signaling. Include hematocrit and hemoglobin measurements in your EPO arm to confirm erythropoietic activity. If EPO doesn't increase red cell mass, dosing was subtherapeutic and the comparison is invalid. The cleanest experimental design pairs ARA-290 against vehicle, EPO against vehicle, and a dual-treatment arm to assess additive versus redundant pathway activation.

The Definitive Truth About ARA-290 in 2026

Here's the honest answer: ARA-290 isn't a commercial therapeutic success story. It's a research tool with unfinished clinical translation. The peptide has been in human trials since 2012, and while early-phase data showed statistically significant improvements in neuropathic pain and small fiber density, no Phase III efficacy trial has secured regulatory approval for a marketed indication. That's not a failure of mechanism. It's a reality of drug development economics and the difficulty of monetizing an off-patent peptide sequence.

What makes ARA-290 valuable in 2026 isn't its FDA status. It's the validated receptor specificity, the mechanistic clarity of IRR pathway activation, and the reproducibility of tissue-protective effects across multiple injury models. If your research question involves isolating innate repair signaling from hematopoietic confounders, or if you're modeling neuropathy, ischemic injury, or inflammatory tissue damage where EPO's erythropoietic effects would complicate interpretation. ARA-290 remains one of the cleanest pharmacological tools available.

The limitation is supply chain fragmentation. ARA-290 isn't sold by major pharma distributors, and cosmetic-grade peptide vendors rarely provide the synthesis documentation or purity verification serious research demands. Our approach at Real Peptides centers on small-batch synthesis with exact amino acid sequencing, third-party HPLC and mass spec verification, and transparent documentation for every production run. We've supplied ARA-290 to research groups studying diabetic neuropathy, ischemia-reperfusion models, and IRR signaling in primary neuronal cultures. The consistent feedback is that purity and batch-to-batch consistency matter more than price when reproducibility is the experimental constraint.

Sourcing ARA-290 for Research in 2026

When evaluating ARA-290 suppliers, the first question isn't price. It's synthesis method and purity verification. Solid-phase peptide synthesis (SPPS) is the standard for research-grade peptides, and the critical quality indicators are HPLC purity (≥98% for in vivo work), mass spectrometry confirmation of correct molecular weight, and amino acid analysis confirming sequence fidelity. A Certificate of Analysis (CoA) should accompany every batch, listing synthesis date, purity percentage, storage conditions, and recommended reconstitution protocol.

What distinguishes cosmetic-grade peptide vendors from research-grade suppliers is third-party verification. Any vendor can generate an in-house HPLC trace. Independent third-party testing (preferably ISO-certified labs) provides the verification research integrity committees and journal reviewers expect. Our process includes both in-house and external validation for every ARA-290 batch, with documentation available for institutional review or publication requirements.

Storage and shipping matter equally. ARA-290 should arrive lyophilized in sealed vials, shipped with desiccant packs and cold packs to prevent moisture exposure during transit. Once received, store at −20°C or colder. Room temperature storage degrades the peptide within weeks. For labs running extended studies, we recommend ordering in smaller batches rather than bulk purchasing six months' supply at once, as peptide stability declines over time even under optimal storage.

If you're comparing suppliers, ask these three questions before purchase: (1) What is the HPLC-verified purity and is third-party documentation available? (2) What synthesis method was used and can you provide batch synthesis records? (3) What is the recommended reconstitution protocol and expected stability post-reconstitution? If a supplier can't answer all three with specific documentation, your research reproducibility is at risk. You can explore our verified ARA-290 2025 latest research dosing options and browse our peptide research collection to see how synthesis transparency supports data integrity.

The research-grade peptide market in 2026 separates into two tiers: vendors optimizing for cost and vendors optimizing for reproducibility. ARA-290's value in mechanistic studies depends entirely on the latter. A 15% price difference is irrelevant if batch variability introduces a 30% error margin in your dose-response curve. For labs where peptide quality directly determines whether the next experiment succeeds or gets retracted, sourcing discipline is not optional.

Questions

ARA-290 is an 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin that selectively activates the innate repair receptor (IRR) — a heterodimer of EPO receptor and CD131 — without binding to the classical homodimeric EPO receptor responsible for red blood cell production. Full-length EPO triggers erythropoiesis by activating homodimeric EPO receptors on erythroid progenitor cells, increasing hematocrit and hemoglobin with associated thrombotic and hypertensive risks. ARA-290 avoids these liabilities entirely while retaining the anti-inflammatory, anti-apoptotic, and tissue-protective signaling mediated by JAK2/STAT3 and PI3K/Akt pathways downstream of IRR activation.

Published clinical trials between 2020 and 2025 used subcutaneous ARA-290 doses ranging from 1 mg to 8 mg per administration, with the most common protocol being 4 mg administered subcutaneously once daily for 28 days. The 2022 sarcoidosis-associated small fiber neuropathy trial used 4 mg daily for four weeks and demonstrated sustained neuropathic pain reduction of 42% through 12-week follow-up. Animal models typically use 0.6–4.0 mg/kg depending on injury severity and species, with ischemia-reperfusion studies favoring 2–4 mg/kg intraperitoneally 30 minutes before reperfusion.

Yes — ARA-290 has demonstrated efficacy in multiple diabetic neuropathy models by restoring intraepidermal nerve fiber density (IENFD) through promotion of Schwann cell survival and axonal regeneration. These tissue-protective effects are mediated by IRR activation and were completely abolished when IRR was genetically knocked down in animal models, confirming receptor specificity. Unlike gabapentinoids or opioids that mask pain symptoms, ARA-290 addresses the underlying pathology of small fiber loss, making it a mechanistically distinct tool for neuropathy research where regeneration rather than analgesia is the experimental endpoint.

Research-grade ARA-290 requires ≥98% purity verified by HPLC and mass spectrometry to ensure reproducible in vivo and in vitro results. Peptide impurities — including truncated sequences, synthesis byproducts, and residual salts — introduce dosing errors and assay variability that compromise data integrity and experimental reproducibility. A 95% pure peptide requires different molarity calculations than a 70% pure preparation, and impurities can alter receptor binding affinity or introduce off-target effects. Third-party verification from ISO-certified labs provides the documentation research integrity committees and journal reviewers expect for publication-quality data.

Reconstitute ARA-290 in sterile water or bacteriostatic saline at 1 mg/mL, then aliquot into single-use volumes and store at −20°C or −80°C to prevent degradation. Repeated freeze-thaw cycles reduce biological activity by up to 40% after three cycles due to peptide aggregation and conformational changes. Once reconstituted, ARA-290 should be used within 30 days if stored at −20°C or within 90 days at −80°C — room temperature storage degrades the peptide within 72 hours even in solution. Never store reconstituted peptide at 4°C for extended periods, as this accelerates hydrolysis of peptide bonds.

In vitro mechanistic studies typically use ARA-290 at concentrations ranging from 10 nM to 10 μM, with 100 nM being the most common starting concentration for IRR activation assays in cell culture. At 100 nM, ARA-290 induces phosphorylation of STAT3 and Akt within 15–30 minutes in IRR-expressing cell lines, confirming receptor engagement at physiologically relevant concentrations. Dose-response experiments usually employ 8-point dilution series from 1 nM to 10 μM to establish EC50 values specific to the cell type and assay readout being used.

No — ARA-290 does not increase hematocrit, hemoglobin, or red blood cell production because it does not activate the homodimeric erythropoietin receptor responsible for erythropoiesis. The thrombotic and hypertensive risks associated with recombinant EPO therapy result from elevated blood viscosity due to increased red cell mass, a liability completely absent with ARA-290. Published studies demonstrate no change in hematocrit or hemoglobin even after repeated dosing at therapeutically effective levels, making ARA-290 a safer alternative for chronic tissue-protective applications where EPO’s hematopoietic effects would be contraindicated.

ARA-290 has demonstrated statistically significant improvements in early-phase clinical trials for neuropathic pain and small fiber neuropathy, but no Phase III efficacy trial has secured regulatory approval for a marketed indication as of 2026. This reflects the economic challenges of developing an off-patent peptide sequence rather than a failure of the underlying mechanism — pharmaceutical companies have limited financial incentive to fund late-stage trials for compounds without strong intellectual property protection. ARA-290 remains valuable as a research tool with validated receptor specificity and reproducible tissue-protective effects across multiple preclinical models.

The innate repair receptor (IRR) — the heterodimeric complex of EPO receptor and CD131 — is expressed in neurons, Schwann cells, endothelial cells, cardiac myocytes, renal tubular epithelial cells, and various immune cell populations including macrophages and dendritic cells. This broad tissue distribution explains ARA-290’s protective effects across diverse injury models including neuropathy, ischemia-reperfusion injury, and inflammatory tissue damage. Before using ARA-290 in a new model system, researchers should confirm IRR expression in their target tissue or cell line via Western blot or qPCR for both EPO-R and CD131 subunits to ensure the peptide’s mechanism is relevant to the experimental question.

Yes — ARA-290 can be combined with other neuroprotective agents to assess additive or synergistic pathway interactions, provided experimental design controls for independent mechanism confirmation. The cleanest approach pairs ARA-290 against vehicle, the comparator compound against vehicle, and a dual-treatment arm to distinguish additive from redundant effects. Because ARA-290 acts through IRR-mediated JAK2/STAT3 and PI3K/Akt signaling, combining it with agents targeting different pathways (e.g., antioxidants, mitochondrial modulators, or anti-inflammatory compounds with distinct targets) allows mechanistic dissection of which protective processes are most critical in a given injury model.

Solid-phase peptide synthesis (SPPS) is the standard method for research-grade ARA-290 production, allowing precise control over amino acid sequence fidelity and minimizing synthesis byproducts that compromise purity. High-quality SPPS protocols use Fmoc (9-fluorenylmethoxycarbonyl) chemistry with rigorous coupling verification at each step, followed by HPLC purification to remove truncated sequences and deletion peptides. The final product should be verified by mass spectrometry to confirm correct molecular weight (approximately 1.3 kDa for ARA-290) and amino acid analysis to validate sequence accuracy — both in-house and third-party testing provide the documentation needed for publication and institutional review.

Lyophilized ARA-290 stored at −20°C or −80°C in sealed vials with desiccant protection remains stable for 12–24 months, with minimal degradation if moisture exposure is prevented. Room temperature storage accelerates hydrolysis and oxidation, reducing peptide activity within weeks even in lyophilized form. Once reconstituted in sterile water or saline, stability depends on storage temperature: −80°C extends viability to 90 days, −20°C to 30 days, and 4°C to less than 7 days. For long-term studies, researchers should order smaller batches rather than bulk purchasing to avoid using aged peptide beyond its guaranteed stability window.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA